PMID- 37612659
OWN - NLM
STAT- MEDLINE
DCOM- 20230825
LR  - 20231122
IS  - 1471-2180 (Electronic)
IS  - 1471-2180 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Aug 23
TI  - Characterization of novel bacteriophage PSKP16 and its therapeutic potential 
      against beta-lactamase and biofilm producer strain of K2-Hypervirulent Klebsiella 
      pneumoniae pneumonia infection in mice model.
PG  - 233
LID - 10.1186/s12866-023-02979-7 [doi]
LID - 233
AB  - BACKGROUND: Severe infections caused by beta- lactamase producers, hypervirulent 
      Klebsiella pneumoniae (BhvKp) with K2 serotype, highlight emergency need for new 
      therapeutic strategies against this pathogen. We aimed to assess the efficacy of 
      a novel phage, PSKP16, in the treating of pneumonia induced by BhvKp in mice 
      models. METHOD: Genome sequences of PSKP16 were analyzed, and associated 
      information can be found in NCBI. We applied treatment in two ways: by using mice 
      for immediate and delayed treatments. Moreover, acute pneumonia obtained by BhvKp 
      with intranasal method, was characterized in terms of histopathology of pulmonary 
      lesions, biomarkers of inflammation level, leukocytes cells infiltration extent 
      in mice, and was assessed treatment of them with PSKP16 multiplicity of infection 
      (MOI: 10), either individually or in combination with gentamicin. Assessment of 
      the ability of PSKP16 to inhibit BhvKp biofilm was studied. RESULTS: PSKP16 was 
      associated with the Drexlerviridae family, and had a genome size of 46,712 bp, 
      and 67 predicted ORFs. Herein, prompt phage administration's efficacy to decrease 
      bacterial load and improve the survival rate in pneumonia models was faster than 
      the synergism model with delay, but both almost displayed similar endpoints. The 
      distribution of BhvKp strains in the lung was consistent with the 
      histopathological findings, simultaneous inflammation, and level of serum tumor 
      necrosis factor-alpha (TNF alpha). The phage treatment presented a lack of severe lesions 
      and alveolar edema, reduction of inflammatory cell infiltration, which not only 
      was it not associated with an over-inflammation but also provided a faster 
      correction of blood cell count abnormalities compared to gentamicin. Phage with a 
      high concentration in in vitro model effectively eliminated biofilms. CONCLUSION: 
      It is essential to raise clinical awareness and management of BhvKp infections, 
      signaled as the next superbug in waiting. The results of our study underscore the 
      importance of PSKP16 as a phage with promising therapeutic potential in treating 
      BhvKp-induced pneumonia.
CI  - (c) 2023. BioMed Central Ltd., part of Springer Nature.
FAU - Rahimi, Sara
AU  - Rahimi S
AD  - Medical Microbiology Research Center, Qazvin University of Medical Sciences, 
      Qazvin, Iran.
AD  - Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran.
FAU - Bakht, Mehdi
AU  - Bakht M
AD  - Medical Microbiology Research Center, Qazvin University of Medical Sciences, 
      Qazvin, Iran.
AD  - Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran.
FAU - Javadi, Amir
AU  - Javadi A
AD  - Medical Microbiology Research Center, Qazvin University of Medical Sciences, 
      Qazvin, Iran.
AD  - Department of Community Medicine, Qazvin University of Medical Sciences, Qazvin, 
      Iran.
FAU - Foroughi, Farshad
AU  - Foroughi F
AD  - Medical Microbiology Research Center, Qazvin University of Medical Sciences, 
      Qazvin, Iran.
AD  - Department of Immunology, School of Medicine, Qazvin University of Medical 
      Sciences, Qazvin, Iran.
FAU - Marashi, Seyed Mahmoud Amin
AU  - Marashi SMA
AD  - Medical Microbiology Research Center, Qazvin University of Medical Sciences, 
      Qazvin, Iran.
FAU - Nikkhahi, Farhad
AU  - Nikkhahi F
AD  - Medical Microbiology Research Center, Qazvin University of Medical Sciences, 
      Qazvin, Iran. Farhadnikkhahi@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20230823
PL  - England
TA  - BMC Microbiol
JT  - BMC microbiology
JID - 100966981
RN  - 0 (Gentamicins)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Bacteriophages/genetics
MH  - Klebsiella pneumoniae
MH  - Inflammation
MH  - Biofilms
MH  - Disease Models, Animal
MH  - Gentamicins
PMC - PMC10464470
OTO - NOTNLM
OT  - Bacteriophage
OT  - Biofilm
OT  - Hypervirulent
OT  - Klebsiella pneumoniae
OT  - Mice model
OT  - beta-lactamase
COIS- The authors declare no competing interests.
EDAT- 2023/08/24 00:42
MHDA- 2023/08/25 06:42
PMCR- 2023/08/23
CRDT- 2023/08/23 23:40
PHST- 2023/04/22 00:00 [received]
PHST- 2023/08/14 00:00 [accepted]
PHST- 2023/08/25 06:42 [medline]
PHST- 2023/08/24 00:42 [pubmed]
PHST- 2023/08/23 23:40 [entrez]
PHST- 2023/08/23 00:00 [pmc-release]
AID - 10.1186/s12866-023-02979-7 [pii]
AID - 2979 [pii]
AID - 10.1186/s12866-023-02979-7 [doi]
PST - epublish
SO  - BMC Microbiol. 2023 Aug 23;23(1):233. doi: 10.1186/s12866-023-02979-7.